generation run 2026-05-08
79 min completedmodel pipeline-v5plan not recordedrun/6327bf66…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- structural_inference
- sparse_evidence
- safety_data_unverified
Reproduce
- inputs
- 39 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
18 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | etizolam anxiety clinical trial | 10 | 8 | All etizolam-specific clinical trials and PK study selected |
| 2 | PubMed | etizolam | 15 | 5 | Selected etizolam-specific papers on toxicology, postmortem data, and clinical use |
| 3 | OpenAlex | etizolam thienodiazepine pharmacology | 12 | 6 | Selected all etizolam-specific papers and key context reviews |
| 4 | ClinicalTrials.gov | etizolam | 1 | 1 | Only registered trial found |
| 5 | PubMed · absence | etizolam pharmacology mechanism action GABA receptor | 0 | — | — |
| 6 | PubMed | etizolam forensic death postmortem blood concentration | 10 | 5 | Selected etizolam-specific forensic/toxicology papers |
| 7 | PubChem | etizolam | 1 | 1 | Primary chemical identity verification |
| 8 | WebSearch | etizolam discovery Yoshitomi Pharmaceutical Japan 1983 synthesis history | 10 | 2 | Historical development data not in academic literature |
| 9 | PubMed | PMID: 15232663 | 1 | 1 | Key drug interaction paper |
| 10 | WebSearch | etizolam Australia Canada legal status | 10 | 2 | International legal status |
| 11 | WebSearch | etizolam GABA-A receptor Ki binding affinity nM | 10 | 2 | Core receptor pharmacology data |
| 12 | PubMed | etizolam dependence withdrawal abuse | 2 | — | — |
| 13 | WebSearch | etizolam legal status DEA scheduling United States controlled substance | 10 | 2 | Key legal status documents for US scheduling |
| 14 | PubChem | CID 3307 | 1 | 1 | Chemical identity verification against brief |
| 15 | WebSearch | etizolam UK legal status Class C | 10 | 2 | UK legal status documentation |
| 16 | WebSearch | etizolam CYP3A4 metabolism oral bioavailability protein binding | 10 | 3 | PK variability data |
| 17 | WebSearch | etizolam melting point physical properties solubility CAS 40054-69-1 | 10 | 1 | Physical property data not in academic literature |
| 18 | PubMed | PMID: 16261363, 28679023 | 2 | 2 | Critical drug interaction and PK variability data |
115 claims by section — every cited sentence, checked against its source
safety32 · 30 ok
At 0.5 mg twice daily, cognitive performance is preserved relative to placebosupported
Non-inferiority crossover study on cognitive performance. j.clinthera.2009.12.010
A comprehensive review concluded that "in therapeutic doses, there is little to suggest that etizolam is more harmful than other benzodiazepines"supported
Higher potency as anxiolytic but lower lethality vs diazepam. Harms predominantly in context of mixed-drug toxicity with illicitly manufactured pills. dar.13052
Animal model data indicate that etizolam has lower acute lethality than diazepamsupported
Higher potency as anxiolytic but lower lethality vs diazepam. dar.13052
In a series of 24 etizolam-positive postmortem cases, multi-drug toxicity was the cause of death in 87.5%, and multiple drugs were detected in all cases: pregabalin (61%), morphine/heroin (54%), diazepam (54%), and benzoylecgonine/cocaine (21%)partially supported
28 postmortem cases. Median femoral blood etizolam 8.5 ng/mL. Polydrug in all cases: pregabalin (61%), morphine/heroin (54%), diazepam (54%). Multi-drug toxicity cause of death in 87.5%. 0025802420973814
Median femoral blood concentration in these postmortem cases was 8.5 ng/mL (range 1.0–172.0 ng/mL)supported
Median femoral blood etizolam 8.5 ng/mL (range 1.0-172.0 ng/mL). 0025802420973814
A separate Japanese autopsy series documented blood concentrations of 85.2–178.2 ng/mL in abuse and overdose cases, with liver tissue concentrations reaching 592.0 ng/g.supported
Blood etizolam 85.2-178.2 ng/mL; liver 592.0 ng/g in abuse cases. j.forsciint.2025.112438
A lethal polydrug poisoning case illustrates the typical fatal scenario: etizolam (86 ng/mL femoral blood) combined with phenobarbital (5082 µg/mL), promethazine, and chlorpromazine — death attributed to the synergistic effect of multiple psychotropic drugs.supported
Fatal poisoning case involving etizolam (86 ng/mL femoral blood), phenobarbital, promethazine and chlorpromazine. Death due to interaction of multiple psychotropic drugs. pmid:21887897
Chronic high-dose use (15 mg/day) produced measurable cognitive impairment: working memory deficits, visuospatial memory deficits, and executive function impairment documented by neuropsychological testingsupported
Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
Drug-induced blepharospasm has been causally linked to both etizolam monotherapy and benzodiazepine combinationssupported
Case report of etizolam and benzodiazepine-induced blepharospasm. jnnp.2003.019869
In a case series of 12 patients with psychotropic-induced blepharospasm (including etizolam as a causative agent), symptoms improved within a mean of 3.9 weeks after drug cessation.supported
12 patients with psychotropic-drug-induced blepharospasm. All improved within 2 months of cessation (mean 3.9 weeks). Etizolam among causative agents. dhps.s20691
Etizolam undergoes significant postmortem decomposition via hemoglobin/H₂O₂-mediated oxidation, generating alpha-hydroxyetizolam and 8-hydroxyetizolam in stored blood samplessupported
Etizolam undergoes postmortem hydroxylation/oxidation via hemoglobin/H2O2. Metabolites alpha-hydroxyetizolam (M1) and M2 form postmortem. bkaf101
Standard immunoassay benzodiazepine screens may not detect etizolam; confirmation requires liquid chromatography with tandem mass spectrometry (LC-MS/MS) or Fourier-transform infrared spectroscopy (FTIR).supported
Immunoassay screens cannot discriminate between BZDs and DBZDs; mass spectrometry required. j.cll.2025.01.013
Ontario, Canada (2017–2021): Most frequently detected benzodiazepine in 11,033 opioid-positive death investigations (54.5% benzodiazepine co-occurrence rate)supported
11,033 death investigations; 54.5% rate of BZD co-involvement. Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination. 1556-4029.15463
Alberta, Canada (2020–2022): Among the most commonly detected benzodiazepines in fentanyl co-ingestion fatalitiessupported
Over 3 years, 2812 fentanyl cases; 45% positive for BZD including etizolam. j.forsciint.2023.111777
International (2019–2020): One of three most frequently detected designer benzodiazepines in postmortem and driving-under-the-influence cases reported to UNODCsupported
Between 2019-April 2020, etizolam among most frequently detected substances in postmortem and DUID cases. ph14060560
Australia (2000–2025): Detected in novel benzodiazepine-related poisoning deathssupported
Deaths due to poisoning involving novel benzodiazepines (NBZDs) are increasing in Australia. Etizolam implicated in cases. j.drugalcdep.2026.113085
Japan: The most commonly abused drug among hypnotic and anxiolytic medicationssupported
Etizolam most commonly abused drug among hypnotic/anxiolytic medications in Japan. j.forsciint.2025.112438
Claim in safety — not_supportednot supportedworking →
Physical and psychological dependence potential is high, comparable to classical benzodiazepinessupported
Etizolam is a thienodiazepine derivative with high affinity for GABA-A receptors. dar.13052
Tamburin et al. (2020) documented high-dose dependence in 11 patients originally prescribed etizolam for medical indications, identified among 1,293 admissions to a benzodiazepine detoxification unitsupported
11 etizolam high-dose users found in 1,293 patients at addiction unit. All prescribed for anxiety/insomnia. fpsyt.2020.601827
Claim in safety — inconclusiveinconclusiveworking →
Etizolam was the most frequently detected benzodiazepine in opioid-positive death investigations in Ontario (2017–2021)supported
Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination. 1556-4029.15463
In Alberta fentanyl fatalities, benzodiazepine-positive cases had higher blood fentanyl concentrations than benzodiazepine-negative cases, suggesting that benzodiazepine co-ingestion may increase fentanyl tolerance or mask respiratory depression warning signs. In vitro drug-drug interaction studies confirmed shared CYP-mediated metabolic pathways between etizolam and oxycodone.supported
Fentanyl concentrations higher in BZD-positive cases. Benzo-dope combination with enhanced CNS depression. j.forsciint.2023.111777
In Alberta fentanyl fatalities, benzodiazepine-positive cases had higher blood fentanyl concentrations than benzodiazepine-negative cases, suggesting that benzodiazepine co-ingestion may increase fentanyl tolerance or mask respiratory depression warning signs. In vitro drug-drug interaction studies confirmed shared CYP-mediated metabolic pathways between etizolam and oxycodone.supported
Oxycodone frequently co-consumed with xylazine, etizolam, diazepam, and methamphetamine. In vitro DDI studies in rat and human liver microsomes. 0113892002446297260217075246
CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, HIV protease inhibitors) significantly increase etizolam plasma concentrations — 1.66-fold in CYP2C19 extensive metabolizers, 2.34-fold in poor metabolizerssupported
Itraconazole increased etizolam AUC 1.66-fold in EMs and 2.34-fold in PMs. jcph.956
The worst-case pharmacokinetic scenario — a CYP2C19 poor metabolizer concurrently taking a potent CYP3A4 inhibitor — produces a 6.18-fold increase in etizolam AUC relative to a CYP2C19 extensive metabolizer without enzyme inhibition.supported
AUC 6.18-fold higher in PMs+itraconazole vs EMs alone. jcph.956
A fatal case combined etizolam with phenobarbital (5082 µg/mL), promethazine, and chlorpromazine.supported
Fatal poisoning case involving etizolam (86 ng/mL femoral blood), phenobarbital, promethazine and chlorpromazine. pmid:21887897
Two Japanese case reports describe serotonin syndrome in patients taking SSRIs (sertraline; paroxetine) concurrently with etizolamsupported
75-year-old woman developed serotonin syndrome with sertraline while also taking etizolam 1mg/day. pmid:19999561
Concurrent opioid use: Synergistic respiratory depression with high fatality risk. This is the single most dangerous combination identified in the epidemiological literature.supported
Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination. 1556-4029.15463
Concurrent opioid use: Synergistic respiratory depression with high fatality risk. This is the single most dangerous combination identified in the epidemiological literature.supported
Benzo-dope combination with enhanced CNS depression. Fentanyl concentrations higher in BZD-positive cases. j.forsciint.2023.111777
CYP2C19 poor metabolizer genotype + CYP3A4 inhibitor co-administration: 6.18-fold increase in plasma exposure creates overdose risk. If co-administration is clinically necessary, substantial dose reduction is required.supported
AUC 6.18-fold higher in PMs+itraconazole vs EMs alone. PM and hEM of CYP2C19 at higher DDI risk. jcph.956
History of substance use disorder: High reinforcement potential due to high affinity and rapid onset. The Tamburin et al. (2020) case series demonstrated prescription-to-dependence trajectories.supported
11 etizolam high-dose users found in 1,293 patients at addiction unit. All prescribed for anxiety/insomnia. fpsyt.2020.601827
pharmacology20 · 18 ok
Etizolam is a positive allosteric modulator (PAM) of GABA-A receptors, binding at the benzodiazepine allosteric site to potentiate chloride ion conductance through GABA-A receptor-gated channelssupported
Etizolam is a thienodiazepine derivative with high affinity for GABA-A receptors. dar.13052
Binding studies in rat cortical membranes demonstrated a Ki of approximately 4.5 nM for displacement of [³H]flunitrazepam — significantly higher affinity than alprazolam (Ki = 7.9 nM) at the same preparationsupported
Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes (cf alprazolam Ki 7.9 nM). pmid:10083975
At recombinant α1β2γ2S GABA-A receptors, etizolam produced an EC₅₀ of 92 nM with a maximum potentiation of 73% of GABA-induced chloride currents, consistent with a partial agonist profile at this subunit combinationsupported
At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents. pmid:10083975
This partial agonist character at α1-containing receptors has been proposed to underlie a potentially reduced burden of sedation, cognitive impairment, and tolerance development relative to full-agonist benzodiazepinessupported
Neurochemical research suggests selectivity for alpha1, beta2, gamma2 GABA-A receptor subunits. Non-inferiority crossover study on cognitive performance. j.clinthera.2009.12.010
The clinical significance of this distinction is debated: high-dose dependence with cognitive deficits has been documented in medical patients prescribed etizolam, suggesting that the partial agonist advantage may not extend to supratherapeutic exposure.supported
11 etizolam high-dose users found in 1,293 patients at addiction unit. All prescribed for anxiety/insomnia. Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
A secondary mechanism distinguishes etizolam from most classical benzodiazepines: it acts as a platelet-activating factor (PAF) receptor antagonistsupported
Effect attributed to platelet-activating factor (PAF) antagonism. pmid:11944589
A secondary mechanism distinguishes etizolam from most classical benzodiazepines: it acts as a platelet-activating factor (PAF) receptor antagonistsupported
Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model. pmid:9416292
This PAF antagonism has been clinically exploited to reduce recurrence of chronic subdural hematoma and investigated for neuroprotective properties in animal models of cortical contusion.supported
Etizolam administered after subdural hematoma removal significantly reduced recurrence vs control. Effect attributed to platelet-activating factor (PAF) antagonism. pmid:11944589
This PAF antagonism has been clinically exploited to reduce recurrence of chronic subdural hematoma and investigated for neuroprotective properties in animal models of cortical contusion.supported
Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model. pmid:9416292
Following oral administration of 0.5 mg in healthy volunteers, etizolam is absorbed with a Tmax of 0.5–2 hourssupported
Maximum plasma concentration attained within 0.5-2 h. pmid:2065698
The earliest human pharmacokinetic study reported a mean elimination half-life (t½) of 3.4 hours following single-dose 0.5 mg oral administrationsupported
Mean elimination half-life averaged 3.4 h. pmid:2065698
Claim in pharmacology — inconclusiveinconclusiveworking →
Multiple-dose administration (0.5 mg twice daily for one week) produced minimal accumulation of the parent compound, and the wash-out half-life was comparable to the single-dose value, suggesting no hepatic enzyme induction or inhibition with repeated dosing at this level.supported
Steady-state rapidly achieved with limited accumulation. pmid:2065698
Etizolam is metabolized primarily by CYP3A4 with clinically significant secondary involvement of CYP2C19supported
Study clarifying involvement of CYP3A4 in etizolam metabolism through itraconazole co-administration study. pmid:15232663
Etizolam is metabolized primarily by CYP3A4 with clinically significant secondary involvement of CYP2C19supported
CYP2C19 polymorphism influences etizolam PK and PD. pmid:16261363
Claim in pharmacology — inconclusiveinconclusiveworking →
8-Hydroxyetizolam (M2): A secondary metabolite identified in human postmortem blood.supported
Metabolites alpha-hydroxyetizolam (M1) and M2 form postmortem. bkaf101
Poor metabolizers (approximately 3–5% of European and 15–20% of East Asian populations) exhibit a 2.65-fold higher area under the curve (AUC) and significantly longer half-life compared to extensive metabolizers.supported
Poor metabolizers had significantly larger AUC and longer t1/2. CYP2C19 polymorphism influences etizolam PK and PD. pmid:16261363
Co-administration of itraconazole (a potent CYP3A4 inhibitor) increased etizolam AUC 1.66-fold in EMs and 2.34-fold in PMssupported
Itraconazole increased etizolam AUC 1.66-fold in EMs and 2.34-fold in PMs. jcph.956
The combined effect of CYP2C19 PM genotype plus CYP3A4 inhibition produces an AUC 6.18-fold higher than in EMs without CYP3A4 inhibition — a pharmacokinetic interaction of major clinical significance that creates substantial overdose risk.supported
AUC 6.18-fold higher in PMs+itraconazole vs EMs alone. jcph.956
comparative-pharmacology11 · 11 ok
The anxiolytic equivalence of etizolam 0.5 mg ≈ alprazolam 0.5 mg ≈ bromazepam 3 mg was established in a direct three-arm comparisonsupported
45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. Equivalent anxiolytic activity. pmid:2572494
At supratherapeutic doses, etizolam produces the full spectrum of benzodiazepine-class effects including profound sedation, amnesia, and respiratory depression in overdose (particularly in combination)partially supported
Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
At supratherapeutic doses, etizolam produces the full spectrum of benzodiazepine-class effects including profound sedation, amnesia, and respiratory depression in overdose (particularly in combination)supported
Harms predominantly in context of mixed-drug toxicity with illicitly manufactured pills. dar.13052
CYP2C19 dependence: Greater pharmacokinetic variability due to CYP2C19 polymorphism than most classical benzodiazepinessupported
CYP2C19 polymorphism influences etizolam PK and PD. pmid:16261363
Bertolino et al. (1989) found etizolam 0.5 mg twice daily superior to both alprazolam 0.5 mg twice daily and bromazepam 1.5 mg twice daily in reducing depressive symptoms in GAD patients, as measured by the Hamilton Depression Rating Scalepartially supported
45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. Equivalent anxiolytic activity; etizolam showed progressive increase in effect over 4 weeks and more antidepressant activity. pmid:2572494
In practice, the vast majority of etizolam-associated fatalities involve polydrug combinations, particularly with opioids.supported
Polydrug in all cases: pregabalin (61%), morphine/heroin (54%), diazepam (54%). Multi-drug toxicity cause of death in 87.5%. 0025802420973814
In practice, the vast majority of etizolam-associated fatalities involve polydrug combinations, particularly with opioids.supported
Etizolam, flualprazolam, flubromazolam and phenazepam implicated in majority of adverse events and deaths. ph14060560
Etizolam's Ki of approximately 4.5 nM in rat cortical membranes represents significantly higher binding affinity than alprazolam (Ki = 7.9 nM) at the benzodiazepine sitesupported
Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes (cf alprazolam Ki 7.9 nM). pmid:10083975
The most significant pharmacological distinction between etizolam and classical benzodiazepines is its partial agonist profile at α1β2γ2S GABA-A receptors (73% maximum potentiation versus near-100% for full agonists like alprazolam and diazepam)supported
At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents. pmid:10083975
Shorter parent half-life (3.4–14.8 hours depending on CYP2C19 genotype) compared to diazepam (20–100 hours) or clonazepam (18–50 hours)supported
Mean elimination half-life averaged 3.4 h. Etizolam classified as short-acting benzodiazepine. pmid:2065698
Active metabolite contribution: Alpha-hydroxyetizolam (t½ 8.2 hours) substantially extends the effective duration of actionsupported
Alpha-hydroxyetizolam metabolite t1/2 8.2 h at steady state. pmid:2065698
history11 · 11 ok
Randomized controlled trials established efficacy in panic disorder with agoraphobia at 0.5 mg twice daily, generalized anxiety disorder at 0.25–0.5 mg twice daily, and GAD with comorbid depressive symptomssupported
30 patients, double-blind RCT, 0.5mg etizolam twice daily for 4 weeks vs placebo for panic disorder with agoraphobia. Significant improvements in anxiety, phobic symptoms, depressive symptoms. pmid:2272192
Randomized controlled trials established efficacy in panic disorder with agoraphobia at 0.5 mg twice daily, generalized anxiety disorder at 0.25–0.5 mg twice daily, and GAD with comorbid depressive symptomssupported
36 patients with GAD, double-blind RCT, 0.25mg or 0.5mg etizolam twice daily vs placebo for 5 weeks. 0.5mg significantly better. pmid:1981698
Randomized controlled trials established efficacy in panic disorder with agoraphobia at 0.5 mg twice daily, generalized anxiety disorder at 0.25–0.5 mg twice daily, and GAD with comorbid depressive symptomssupported
30 female patients, double-blind, etizolam vs alprazolam 0.5mg BID for 5 weeks. Both drugs equivalent for anxiolytic/antidepressant activity. pmid:2692969
A three-arm comparative trial found etizolam 0.5 mg comparable in anxiolytic effect to alprazolam 0.5 mg and bromazepam 3 mg, with a notably stronger antidepressant component.supported
45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. Equivalent anxiolytic activity; etizolam showed progressive increase in effect over 4 weeks and more antidepressant activity. pmid:2572494
A 2009 multicenter RCT specifically examined cognitive safety, finding that 0.5 mg twice daily for three weeks produced no significant cognitive impairment relative to placebosupported
Non-inferiority crossover study on cognitive performance. j.clinthera.2009.12.010
Subsequent evidence of severe cognitive deficits at high doses (15 mg/day) in dependent patients tempered this conclusion.supported
Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
In Alberta from 2020–2022, it was among the most commonly detected benzodiazepines in fentanyl co-ingestion fatalities.supported
Over 3 years, 2812 fentanyl cases; 45% positive for BZD including etizolam. j.forsciint.2023.111777
Pharmacological investigation also revealed an unexpected secondary mechanism: etizolam acts as a platelet-activating factor (PAF) receptor antagonist, a property that led to clinical exploration in chronic subdural hematoma.supported
Etizolam administered after subdural hematoma removal significantly reduced recurrence vs control. Effect attributed to platelet-activating factor (PAF) antagonism. pmid:11944589
While remaining a legal prescription medication in Japan, India, and Italy, etizolam began appearing in illicit drug markets and online research chemical vendors approximately from 2007 onward, initially in Europe and subsequently in North Americasupported
First designer BZDs appeared as NPS around 2007. 29 designer BZDs notified to EMCDDA. 1570159x18666200110121333
By the mid-2010s, etizolam had become one of the three most frequently detected designer benzodiazepines in postmortem and driving-under-the-influence cases reported to the United Nations Office on Drugs and Crimepartially supported
Between 2019-April 2020, etizolam among most frequently detected substances in postmortem and DUID cases. ph14060560
Its presence in the unregulated opioid supply became a particular concern: in Ontario from 2017–2021, etizolam was the most frequently detected benzodiazepine in 11,033 opioid-positive death investigationssupported
11,033 death investigations; 54.5% rate of BZD co-involvement. Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination. 1556-4029.15463
neuroscience11 · 9 ok
Class-level data from early thienodiazepine research (using Y-7131, a related thienodiazepine precursor) demonstrated significant REM sleep suppression at 2 mg without REM rebound on discontinuationsupported
Effects of clotiazepam and Y-7131 (early thienodiazepine) on normal human sleep vs diazepam and nitrazepam. REM suppression at 2mg Y-7131 without rebound. pmid:709
The De Candia et al. (2009) trial, showing preserved cognition at 0.5 mg twice daily, is consistent with this predictionsupported
Non-inferiority crossover study on cognitive performance. j.clinthera.2009.12.010
The Tamburin et al. (2020) high-dose data, showing severe cognitive impairment at 15 mg/day, suggests the partial agonist ceiling is exceeded or overridden at supratherapeutic doses.supported
Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
Neuroplasticity effects: Do chronic etizolam exposure and withdrawal alter GABA-A receptor subunit expression in human brain? The cognitive deficits observed at high doses may reflect such neuroadaptation, but neuroimaging confirmation is lacking.supported
Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
Claim in neuroscience — inconclusiveinconclusiveworking →
Etizolam's reported preferential activity at α1β2γ2-containing receptors complicates this model: α1-containing receptors are more closely associated with sedation and amnesia than with anxiolysissupported
Neurochemical research suggests selectivity for alpha1, beta2, gamma2 GABA-A receptor subunits. j.clinthera.2009.12.010
More subjects reported drowsiness after etizolam than after clotiazepam or placebo, consistent with a sedation profile tilted toward global cortical inhibition rather than selective attentional effects.supported
More subjects reported drowsiness after etizolam. pmid:1363923
Claim in neuroscience — not_supportednot supportedworking →
Etizolam's partial agonist profile at α1β2γ2S receptors positions it as a test case for this model: if the α1 partial agonism truly reduces the sedation ceiling while preserving α2/α3-mediated anxiolysis, etizolam should show a wider therapeutic window between anxiolytic and sedative dosessupported
At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents. pmid:10083975
Etizolam's PAF receptor antagonism places it at an intersection of GABAergic pharmacology and neuroinflammatory modulationsupported
Effect attributed to platelet-activating factor (PAF) antagonism. pmid:11944589
The neuroprotective effects observed in animal models of cortical contusion suggest a dual mechanism — immediate anxiolysis via GABA-A potentiation plus longer-term neuroprotection via reduced neuroinflammation — that has not been systematically explored.supported
Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model. Evidence that PAF is involved in microthrombosis formation following TBI. pmid:9416292
summary9 · 9 ok
Its binding affinity at the benzodiazepine site (Ki ≈ 4.5 nM in rat cortical membranes) exceeds that of alprazolam (Ki = 7.9 nM).supported
Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes (cf alprazolam Ki 7.9 nM). pmid:10083975
Multiple randomized controlled trials from the late 1980s through 2009 established anxiolytic efficacy at 0.5–1 mg twice dailypartially supported
36 patients with GAD, double-blind RCT, 0.25mg or 0.5mg etizolam twice daily vs placebo for 5 weeks. 0.5mg significantly better. pmid:1981698
From approximately 2007, etizolam emerged as one of the most prevalent novel psychoactive substance benzodiazepines in illicit drug markets globally, culminating in permanent Schedule I classification in the United States effective April 2026.partially supported
First designer BZDs appeared as NPS around 2007. 29 designer BZDs notified to EMCDDA. 1570159x18666200110121333
Etizolam acts as a positive allosteric modulator at GABA-A receptors, binding the benzodiazepine site with a Ki of approximately 4.5 nM in rat cortical membranes and exhibiting a partial agonist profile at α1β2γ2S subunit combinations (EC₅₀ = 92 nM, 73% maximum potentiation)supported
Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes. At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents. pmid:10083975
An additional mechanism as a platelet-activating factor receptor antagonist distinguishes it pharmacologically from classical benzodiazepines.supported
Effect attributed to platelet-activating factor (PAF) antagonism. pmid:11944589
Cognitive impairment is minimal at therapeutic doses but pronounced above 5 mg. Disinhibition, compulsive redosing, and delusions of sobriety are reported at supratherapeutic doses.partially supported
Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
Etizolam alone exhibits relatively low acute lethality — lower than diazepam in animal models — but fatalities escalate sharply in combination with opioids or alcoholsupported
Higher potency as anxiolytic but lower lethality vs diazepam. Harms predominantly in context of mixed-drug toxicity with illicitly manufactured pills. dar.13052
In Ontario from 2017–2021, it was the most frequently detected benzodiazepine in opioid-positive death investigationssupported
Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination. 1556-4029.15463
CYP2C19 poor metabolizers experience 2.65-fold higher plasma exposure, a pharmacogenomic variable absent from most harm reduction guidancesupported
Poor metabolizers had significantly larger AUC and longer t1/2. CYP2C19 polymorphism influences etizolam PK and PD. pmid:16261363
pharmacokinetic-detail8 · 5 ok
The primary human pharmacokinetic study administered 0.5 mg oral etizolam as single and multiple doses in healthy volunteers:supported
The pharmacokinetics of etizolam, a new thienodiazepine derivative, has been examined after single and multiple (0.5 mg tablet) oral therapeutic doses in healthy volunteers. pmid:2065698
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Fracasso et al. (1991) reported a mean t½ of 3.4 hours in healthy volunteers, while Fukasawa et al. (2005) reported 10.5 ± 3.9 hours for CYP2C19 extensive metabolizers and 14.8 ± 4.2 hours for poor metabolizerssupported
Mean elimination half-life averaged 3.4 h. pmid:2065698
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Fukasawa et al. (2005) demonstrated that CYP2C19 polymorphism profoundly influences etizolam pharmacokinetics:supported
CYP2C19 polymorphism influences etizolam PK and PD. pmid:16261363
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
8-Hydroxyetizolam (M2) is a secondary metabolite identified in human postmortem blood samplessupported
Metabolites alpha-hydroxyetizolam (M1) and M2 form postmortem. bkaf101
The wash-out kinetics after one week of dosing were comparable to single-dose kinetics, arguing against auto-induction. In vitro drug-drug interaction studies between etizolam and oxycodone in rat and human liver microsomes have been conducted, confirming shared CYP-mediated metabolic pathways.partially supported
Steady-state rapidly achieved with limited accumulation. pmid:2065698
clinical-evidence6 · 6 ok
Casacchia et al. (1990) conducted a double-blind, placebo-controlled trial in 36 patients with GAD, randomized to etizolam 0.25 mg twice daily, etizolam 0.5 mg twice daily, or placebo for 5 weekssupported
36 patients with GAD, double-blind RCT, 0.25mg or 0.5mg etizolam twice daily vs placebo for 5 weeks. pmid:1981698
Bertolino et al. (1989) conducted a three-arm comparative trial (n=45) comparing etizolam 0.5 mg twice daily, alprazolam 0.5 mg twice daily, and bromazepam 1.5 mg twice daily over 4 weeks in GAD patientspartially supported
45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. pmid:2572494
De Candia et al. (2009) conducted the most methodologically rigorous trial: a multicenter, randomized, double-blind, placebo-controlled, crossover study examining cognitive performance during 3 weeks of etizolam 0.5 mg twice daily in patients with anxiety disorderssupported
Non-inferiority crossover study on cognitive performance. j.clinthera.2009.12.010
Tamburin et al. (2020) documented severe cognitive deficits in patients with high-dose etizolam dependence (up to 15 mg/day): working memory impairment, visuospatial memory deficits, and executive function impairment were identified in neuropsychological testingsupported
Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day. fpsyt.2020.601827
Pariante et al. (1989) compared etizolam to alprazolam in 30 female patients with GAD associated with depressive symptoms over 5 weekssupported
30 female patients, double-blind, etizolam vs alprazolam 0.5mg BID for 5 weeks. pmid:2692969
Singla et al. (2025) conducted a contemporary randomized clinical trial comparing etizolam premedication to music distraction for improving inferior alveolar nerve block success in patients with symptomatic irreversible pulpitissupported
RCT comparing etizolam vs music distraction for dental anxiety in patients with irreversible pulpitis. 24-0028
receptor-pharmacology6 · 6 ok
The primary quantitative binding data come from rat cortical membrane preparations and recombinant receptor studies:supported
Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes. At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents. pmid:10083975
The sub-maximal potentiation (73%) at α1β2γ2S receptors classifies etizolam as a partial agonist at this subunit combinationsupported
At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents. pmid:10083975
Neurochemical research has suggested preferential selectivity for the α1β2γ2 GABA-A receptor subunit combination relative to other subunit assemblies, though the extent of this selectivity and its clinical impact at supratherapeutic doses remain incompletely characterizedsupported
Neurochemical research suggests selectivity for alpha1, beta2, gamma2 GABA-A receptor subunits. j.clinthera.2009.12.010
Computational docking and quantitative structure-activity relationship (QSAR) analyses of designer benzodiazepines, including etizolam, have been conducted to predict relative GABA-A binding affinities across the classsupported
QSAR models and molecular docking on GABA-A receptors for 101 designer BZDs identified online. ph14080720
Etizolam's secondary activity as a platelet-activating factor (PAF) receptor antagonist is distinct from its benzodiazepine-site actionsupported
Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model. pmid:9416292
In a clinical context, etizolam's PAF antagonism was exploited to attenuate recurrence of chronic subdural hematoma, with CT-documented reduction in hematoma volumesupported
Etizolam administered after subdural hematoma removal significantly reduced recurrence vs control. Effect attributed to platelet-activating factor (PAF) antagonism. pmid:11944589
chemistry1 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →